SynthesisBMC pulmonary medicine2023

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.

Di Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.